<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02252081</url>
  </required_header>
  <id_info>
    <org_study_id>ENDA-014-13F</org_study_id>
    <secondary_id>1I01CX000982-01A1</secondary_id>
    <nct_id>NCT02252081</nct_id>
  </id_info>
  <brief_title>Metformin in Kidney Disease</brief_title>
  <official_title>Dysmetabolism of Chronic Kidney Disease and Vascular Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic kidney disease (CKD) is a major global health problem associated with substantial&#xD;
      costs and resource utilization. Currently, CKD affects more than 500 million people&#xD;
      worldwide. Patients with CKD have unacceptably high mortality rates due to cardiovascular&#xD;
      (CV) causes, which are not entirely explained by traditional CV risk factors. The mortality&#xD;
      rates in advanced CKD are six times higher compared to the Medicare population, with CVD&#xD;
      accounting for the overwhelming majority of deaths. Insulin resistance (IR) is common in CKD&#xD;
      patients and may represent a central link between CKD and the increased CVD risk observed in&#xD;
      this population. Insulin resistance may increase CV risk by impairing and worsening&#xD;
      endothelial function, increasing reactive oxygen species, and exacerbating systemic&#xD;
      inflammation-hence, insulin resistance is considered a &quot;non-traditional CV risk factor&quot; in&#xD;
      CKD.&#xD;
&#xD;
      Obesity (defined by a body mass index [BMI] of at least 30 kg/m2) is a major public health&#xD;
      problem-the upward trend in obesity prevalence across regions and continents is a worldwide&#xD;
      concern. Obesity increases the risk for cardiovascular disease and death. In the general&#xD;
      population, obesity hastens death by 9.4 years. Obesity is an independent risk factor for&#xD;
      CKD. Besides its contribution to the development of diabetes and hypertension, increased fat&#xD;
      mass may also have a direct impact on kidney function.&#xD;
&#xD;
      In spite of the increasing prevalence of both obesity and CKD, the impact of obesity in the&#xD;
      CKD population is not known, especially in terms of the exaggerated metabolic disturbances&#xD;
      associated with their coexistence. It is highly likely that these two conditions have&#xD;
      profound interactions that exaggerate the severity of the metabolic derangements when they&#xD;
      coexist, particularly in regards to adipokine dysregulation, the risk of &quot;insulin&#xD;
      resistance&quot;, and downstream effects on vascular health. The current proposal will attempt to&#xD;
      characterize the relative and combined impact of both obesity and CKD on metabolic&#xD;
      disturbances, which may aid in risk stratification and identifying specific targets for&#xD;
      intervention.&#xD;
&#xD;
      The ultimate goal of this proposal is to understand the relative and combined impact of&#xD;
      obesity and CKD on the generation and maintenance of insulin resistance and their impact on&#xD;
      cardiovascular health.&#xD;
&#xD;
      Specific Aim 2: To study the effects of metformin, an AMPK activator, on metabolic&#xD;
      disturbances associated with obesity and moderate CKD.&#xD;
&#xD;
      S.A.2.a: To test if metformin will improve LAR in obese patients with moderate CKD compared&#xD;
      to placebo.&#xD;
&#xD;
      S.A.2.b: To test if metformin will improve markers of systemic inflammation, oxidative&#xD;
      stress, endothelial dysfunction in obese patients with moderate CKD compared to placebo.&#xD;
&#xD;
      S.A.2.c: To test if metformin will improve atherosclerosis markers and reduce clinical CVD&#xD;
      events in obese patients with moderate CKD compared to placebo.&#xD;
&#xD;
      Hypothesis: The investigators hypothesize that the administration of metformin in obese CKD&#xD;
      patients will significantly improve the adipokine profiles-particularly through a reduction&#xD;
      in LAR. Additionally, that it will improve systemic inflammation, oxidative stress and&#xD;
      endothelial function, which may or may not be mediated by changes in adipokines. Finally, the&#xD;
      investigators hypothesize that improvements in these markers of vascular health will&#xD;
      translate into reduced arterial stiffness and less clinical CV events&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2014</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change is Leptin to Adiponectin Ratio (LAR)</measure>
    <time_frame>16 weeks after start of treatment</time_frame>
    <description>Change in leptin to adiponectin ratio (LAR) after 4 months of metformin vs. placebo will be assessed as a biomarker of insulin resistance in CKD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Flow-mediated Dilation (FMD)</measure>
    <time_frame>16 weeks after the start of treatment</time_frame>
    <description>Change in FMD after 4 months of treatment with metformin will be compared to change in the placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aortic Pulse-wave Velocity (aPWV)</measure>
    <time_frame>16 weeks after starting treatment</time_frame>
    <description>is a measurement of stiffening of the large elastic arteries and atherosclerosis. It is a subclinical marker of cardiovascular disease</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Estimated Glomerular Filtration Rate (eGFR)</measure>
    <time_frame>baseline and 16 weeks after starting treatment</time_frame>
    <description>eGFR is a measurement of kidney function, this was a descriptive measurement</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500 to 1500 mg orally per day for 16 weeks if eGFR &gt; 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =&lt; 45 ml/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo pill(s) orally per day for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>500 to 1500 mg orally per day for 16 weeks if eGFR &gt; 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =&lt; 45 ml/min</description>
    <arm_group_label>metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo pill(s) orally per day for 16 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years old;&#xD;
&#xD;
          -  Ability to give informed consent;&#xD;
&#xD;
          -  Life expectancy greater than 6 months;&#xD;
&#xD;
          -  Estimated GFR 30-59 ml/min/1.73m^2;&#xD;
&#xD;
          -  Overweight (BMI &gt;=25 to &lt; 30 kg/m^2) or obese (BMI &gt;=30 kg/m^2); or normal (BMI &gt;=18.5&#xD;
             to &lt;25 kg/m^2) if pre-diabetic or insulin resistant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breast feeding;&#xD;
&#xD;
          -  Presence or history of Diabetes Mellitus type I or II&#xD;
&#xD;
          -  History of metformin use or any insulin sensitizer or any drug for the treatment of&#xD;
             metabolic syndrome over the last one year;&#xD;
&#xD;
          -  Any acute kidney injury episode in the last 4 months due to the risk of recurrent AKI;&#xD;
&#xD;
          -  Proteinuria of &gt; 5 g in 24 hours determined by a 24 hour urine collection or PCR &gt;&#xD;
             4.5;&#xD;
&#xD;
          -  Uncontrolled hypertension with systolic blood pressure 160 mmHg and diastolic blood&#xD;
             pressure 100 mmHg;&#xD;
&#xD;
          -  Patients with new changes to their antihypertensive regimen over the last 1 month;&#xD;
&#xD;
          -  Severe, unstable, or active inflammatory disease; active infection including&#xD;
             seropositive HIV, Hepatitis B or C; active connective tissue disorder; or moderate to&#xD;
             severe liver disease;&#xD;
&#xD;
          -  Decompensated heart failure;&#xD;
&#xD;
          -  Recent hospitalization or surgical procedure within 1 month prior to the study for any&#xD;
             cause;&#xD;
&#xD;
          -  Current active malignancy or cancer history in the prior 5 years (excluding squamous&#xD;
             cell and basal cell skin cancers);&#xD;
&#xD;
          -  Known intolerance to the study drug;&#xD;
&#xD;
          -  Patient receiving oral or injected steroids&#xD;
&#xD;
          -  Use of any investigational product or device within 30 days prior to screening, or&#xD;
             requirement for any investigational agent prior to completion of all scheduled study&#xD;
             assessments;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adriana M Hung, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tennessee Valley Healthcare System Nashville Campus, Nashville, TN</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tennessee Valley Healthcare System Nashville Campus, Nashville, TN</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212-2637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 25, 2014</study_first_submitted>
  <study_first_submitted_qc>September 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2014</study_first_posted>
  <results_first_submitted>July 20, 2021</results_first_submitted>
  <results_first_submitted_qc>October 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 4, 2021</results_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metformin</keyword>
  <keyword>cardiovascular disease</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Metabolic Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No we do not plan to make individual level data available.&#xD;
This is a pilot mechanistic study.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT02252081/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>65 patients did not meet inclusion criteria (normal GFR or to low GFR, new diabetes diagnosis, uncontrolled hypertension) or decline to participate.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Metformin</title>
          <description>500 to 1500 mg orally per day for 16 weeks if eGFR &gt; 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =&lt; 45 ml/min&#xD;
metformin: 500 to 1500 mg orally per day for 16 weeks if eGFR &gt; 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =&lt; 45 ml/min</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo pill(s) orally per day for 16 weeks&#xD;
Placebo: placebo pill(s) orally per day for 16 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non compliance &amp; others</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metformin</title>
          <description>500 to 1500 mg orally per day for 16 weeks if eGFR &gt; 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =&lt; 45 ml/min&#xD;
metformin: 500 to 1500 mg orally per day for 16 weeks if eGFR &gt; 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =&lt; 45 ml/min</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo pill(s) orally per day for 16 weeks&#xD;
Placebo: placebo pill(s) orally per day for 16 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" lower_limit="64" upper_limit="72"/>
                    <measurement group_id="B2" value="66" lower_limit="58" upper_limit="72"/>
                    <measurement group_id="B3" value="67" lower_limit="60" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change is Leptin to Adiponectin Ratio (LAR)</title>
        <description>Change in leptin to adiponectin ratio (LAR) after 4 months of metformin vs. placebo will be assessed as a biomarker of insulin resistance in CKD</description>
        <time_frame>16 weeks after start of treatment</time_frame>
        <population>analyzed as log transformed using ANCOVA of change, ng/µg (log transformed value)</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>metformin 500 to 1500 mg orally per day for 16 weeks if eGFR &gt; 45 ml/min/1.73m^2; 500 to 1000 mg orally per day for 16 weeks if eGFR =&lt; 45 ml/min/1.73m^2&#xD;
Placebo: placebo pill(s) orally per day for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo pill(s) orally per day for 16 weeks&#xD;
Placebo: placebo pill(s) orally per day for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change is Leptin to Adiponectin Ratio (LAR)</title>
          <description>Change in leptin to adiponectin ratio (LAR) after 4 months of metformin vs. placebo will be assessed as a biomarker of insulin resistance in CKD</description>
          <population>analyzed as log transformed using ANCOVA of change, ng/µg (log transformed value)</population>
          <units>ng/micrograms</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="1.5" upper_limit="3.2"/>
                    <measurement group_id="O2" value="1.3" lower_limit="0.6" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="1.0" upper_limit="2.6"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0.5" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Flow-mediated Dilation (FMD)</title>
        <description>Change in FMD after 4 months of treatment with metformin will be compared to change in the placebo group.</description>
        <time_frame>16 weeks after the start of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>500 to 1500 mg if eGFR &gt; 45 ml/min; 500 to 1000 mg if eGFR =&lt; 45 ml/min&#xD;
metformin: 500 to 1500 mg if eGFR &gt; 45 ml/min; 500 to 1000 mg if eGFR =&lt; 45 ml/min</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo pill(s) orally per day for 16 weeks&#xD;
Placebo: placebo pill(s) orally per day for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Flow-mediated Dilation (FMD)</title>
          <description>Change in FMD after 4 months of treatment with metformin will be compared to change in the placebo group.</description>
          <units>change in percent</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="3.2" upper_limit="8.4"/>
                    <measurement group_id="O2" value="5.0" lower_limit="3.7" upper_limit="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="5.4" upper_limit="18.8"/>
                    <measurement group_id="O2" value="6.2" lower_limit="4.2" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aortic Pulse-wave Velocity (aPWV)</title>
        <description>is a measurement of stiffening of the large elastic arteries and atherosclerosis. It is a subclinical marker of cardiovascular disease</description>
        <time_frame>16 weeks after starting treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>500 to 1500 mg orally per day for 16 weeks if eGFR &gt; 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =&lt; 45 ml/min</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>500 to 1500 mg orally per day for 16 weeks if eGFR &gt; 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =&lt; 45 ml/min</description>
          </group>
        </group_list>
        <measure>
          <title>Aortic Pulse-wave Velocity (aPWV)</title>
          <description>is a measurement of stiffening of the large elastic arteries and atherosclerosis. It is a subclinical marker of cardiovascular disease</description>
          <units>cm/s</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline aPWV (cm/s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" lower_limit="8.2" upper_limit="11.4"/>
                    <measurement group_id="O2" value="9.8" lower_limit="8.4" upper_limit="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week16 aPWC (cm/s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" lower_limit="8.9" upper_limit="10.9"/>
                    <measurement group_id="O2" value="9.9" lower_limit="8.6" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Estimated Glomerular Filtration Rate (eGFR)</title>
        <description>eGFR is a measurement of kidney function, this was a descriptive measurement</description>
        <time_frame>baseline and 16 weeks after starting treatment</time_frame>
        <population>kidney function measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>metformin: 500 to 1500 mg orally per day if eGFR &gt; 45 ml/min/1.73m^2; 500 to 1000 mg orally per day if eGFR =&lt; 45 ml/min/1.73m^2 orally per day for 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matching placebo pill(s) 500 to 1500 mg orally per day if eGFR &gt; 45 ml/min/1.73m^2; 500 to 1000 mg orally per day if eGFR =&lt; 45 ml/min/1.73m^2 orally per day for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Glomerular Filtration Rate (eGFR)</title>
          <description>eGFR is a measurement of kidney function, this was a descriptive measurement</description>
          <population>kidney function measurement</population>
          <units>ml/min</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline GFR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.5" lower_limit="46.5" upper_limit="54.2"/>
                    <measurement group_id="O2" value="48.5" lower_limit="45.4" upper_limit="56.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 GFR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="45.25" upper_limit="54.9"/>
                    <measurement group_id="O2" value="48.7" lower_limit="43.9" upper_limit="56.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 weeks</time_frame>
      <desc>clinicaltrials.gov definitions</desc>
      <group_list>
        <group group_id="E1">
          <title>Metformin</title>
          <description>500 to 1500 mg orally per day for 16 weeks if eGFR &gt; 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =&lt; 45 ml/min&#xD;
metformin: 500 to 1500 mg orally per day for 16 weeks if eGFR &gt; 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =&lt; 45 ml/min</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo pill(s) orally per day for 16 weeks&#xD;
Placebo: placebo pill(s) orally per day for 16 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pericarditis &amp; chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonia &amp; pneumonia related complications</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlactetemia without acidosis &gt;3.5 mmol/L</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>safety labs at baseline, 2,4,8,12 &amp;16 weeks</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea/loose stools/flatulence</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>left lower quadrant pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Adriana Hung</name_or_title>
      <organization>Nashville Campus TVHS</organization>
      <phone>6153274751 ext 6731</phone>
      <email>adriana.hung@va.goc</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

